Van Berckelaer, C. http://orcid.org/0000-0003-4082-9799
Rypens, C.
van Dam, P.
Pouillon, L.
Parizel, M.
Schats, K. A.
Kockx, M.
Tjalma, W. A. A.
Vermeulen, P.
van Laere, S.
Bertucci, F.
Colpaert, C.
Dirix, L.
Funding for this research was provided by:
Fonds Wetenschappelijk Onderzoek (grant number 1189617N)
Article History
Received: 22 May 2018
Accepted: 25 January 2019
First Online: 18 February 2019
Ethics approval
: This study is conducted in accordance with the ethical standards of the University of Antwerp and received ethical approval from the ethics committee (File number: 16/33/338).
: Not applicable.
: K.S. is an employee of HistoGeneX NV. M.K. is the CEO of HistoGeneX NV, which performs immunohistochemistry and molecular testing for pharmaceutical companies as part of (pre)clinical studies that evaluate new anticancer drugs. Other authors declare that they have no competing interests.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.